From Clinical Trial Efficacy to Real-World Effectiveness First Ajovy® ▼ (fremanezumab) Data from European Real World Evidence Program | Business Wire

November 13, 2021

AMSTERDAM–( BUSINESS WIRE )–8 November 2021, Teva Germany (GmbH) presented at the DGN Congress 2021 the first interim analysis results of the FINESSE study aiming to provide real-world evidence of fremanezumab treatment outcomes by evaluating effectiveness in routine clinical practice.

Read the source article at
2021-11-08 00:00:00

Share This Story!